AP NEWS

Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight 2018 - ResearchAndMarkets.com

December 21, 2018

DUBLIN--(BUSINESS WIRE)--Dec 21, 2018--The  “Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2018”  drug pipelines has been added to  ResearchAndMarkets.com’s  offering.

Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2018 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist Pipeline Products in Clinical Stages

6. Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Companies Mentioned

CapGenesis Therapeutics Flex Pharma Medifron DBT Centrexion Therapeutics Winston Pharmaceuticals NeurogesX

For more information about this drug pipelines report visit  https://www.researchandmarkets.com/research/ljsmds/transient?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181221005303/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Analgesics

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/21/2018 09:57 AM/DISC: 12/21/2018 09:57 AM

http://www.businesswire.com/news/home/20181221005303/en

AP RADIO
Update hourly